Bullish
SMI Index rises 0.34% to 14,334.79; Novartis gains 6.25% on positive drug data
The Swiss Market Index (SMI) increased by 0.34% to close at 14,334.79 on September 1, 2026. Novartis led the gains with a 6.25% rise following positive late-stage data for its multiple sclerosis drug. Other SMI components showed mixed performance, with notable declines in Partners Group Holding AG (-7.26%) and Roche Holding AG (-1.50%).
Key points
- Novartis shares surged 6.25% after announcing positive late-stage results for its multiple sclerosis drug.
- Partners Group Holding AG's stock plummeted 7.26%, and Roche Holding AG's shares fell 1.50%, contributing to the index's mixed performance.
- The SMI's overall gain of 0.34% reflects a recovery from previous declines, indicating market stabilization.
Sources
- Swiss Market Index Recovers; Novartis Gains Amid Positive Late-stage Multiple Sclerosis Drug DataMarketScreener · September 1, 2026
- INDEX-MONITOR: Galderma und Sandoz neu im SMI - Kühne+Nagel und Swisscom rausonvista · July 8, 2026
- SMI sempre più orientato al settore farmaceutico ma gli esperti non sono preoccupatilaRegione.ch · July 9, 2026
- S&P 500 Capped 35/20 Utilities & Telecommunication Sector IndexS&P Dow Jones Indices · September 1, 2026
AI-generated from public news sources. Not financial advice.
